INSIDE: - Medical Device Daily

More documents

Recommendations

Info

TUESDAY, JANUARY 31, 2006 MEDICAL DEVICE DAILY PAGE 8 OF 10BarrxContinued from Page 1precursor to cancer. And when Barrett’s is not controlled, itcan then become a cancer that has a discouraging 90%fatality rate, and the interventions are highly invasive.Targeting the treatment of Barrett's, the Halo 360 Systemprovides increasing evidence of successful treatmentof this condition, and Barrx recently hailed publication of anew study, "Thin Layer Ablation of Human EsophagealEpithelium Using a Bipolar Radiofrequency Balloon Device,"as demonstrating the safety and efficacy of the system.Specifically, the study, appearing in the January issueof Surgical Endoscopy, the journal of the Society of AmericanGastrointestinal and Endoscopic Surgeons (SAGES;Chicago) demonstrated the ability of Halo to kill the precancerouscells without damaging healthy tissue. Significantly,this allowed the re-growth of normal cells.Thirteen male patients aged 49-85, all diagnosed withesophageal adenocarcinoma, were enrolled in this studyintended to determine the optimal energy density andtreatment parameters to achieve the complete removal ofhuman esophageal epithelium. The study was designed asa pilot trial leading up to the use of this device in patientswith Barrett’s.Patients underwent randomization into three groups,with each group receiving slightly different energy doseswhen treated with the HALO 360 System. Endoscopy wasperformed, followed by positioning of the HALO 360 ablationcatheter within the esophagus.The procedure is performed without incisions, underconscious sedation, and requires an average of less than30 minutes to complete. The physician first uses a HALO 360sizing balloon catheter to dilate the esophagus and determineits inner diameter. An ablation catheter is theninflated within the diseased area and the system’s energygenerator then delivers to the area a less than one secondburst – which the company has described as a “flash burn”not producing a great deal of heat – to the area, removingless than a 1 mm layer of diseased tissue.New healthy tissue replaces the ablated Barrett’s tissuein three to four weeks for most patients, according to thetrial results.In this particular study, the treatment was followed bya total esophagectomy (removal of the esophagus) as indicatedby the cancer diagnosis – a part of the stomachpulled up and used as a substitute esophagus in a highlyinvasive procedure (but necessary without any other treatmentavailable). Pathological evaluation was performed onthe ablated segments to determine the ablation depth andcompleteness of epithelial removal.Results confirm that the HALO 360 System is capable ofremoving the esophageal epithelium without causinguntoward injury to the underlying structures. Somepatients have minor discomfort which is managed withmedication, and following treatment patients may resumeacid suppression therapy.Brian Dunkin, MD, associate professor of surgery andchief of the division of laparoendoscopic surgery at theUniversity of Miami Miller School of Medicine, and hiscolleagues did most of the procedures and provided oversightof all of the pathology.He told Medical Device Daily that the HALO 360 systemoffers the opportunity of a “preemptive strike” vs. esophagealcancer that is "extremely easy to use, [the effects]extremely reproducible and very well controlled.“The data basically allowed us to choose the properenergy setting,” with 10 joules and 12 joules being the mostefficient, Dunkin said.He noted that other systems tend to offer “point andshoot” approaches. Rather than “pointing and cooking,”HALO 360 treatment is extremely uniform, he said. And someof these systems produce “strictures” within the esophagus,a loss of elasticity and difficulty in swallowing, he added.The HALO 360 System was FDA-approved in 2001 butnot commercialized until late 2004, with 2005 sales ofabout $1 million, according to the president of Barrx, GregBarrett, whose name, of course, resonates rather ironicallyin this context.“What we have been doing is pursuing a number ofclinical studies to validate the technology as to both safetyand efficacy, and we really wanted to understand betterhow the technology works,” Barrett said, with the sale of asecond-generation device now in full ramp-up.“What we are trying to do is ablate this condition at avery early stage, and even at the late stage, to avoid anesophageal cancer. We have gone through exhaustive studiesto demonstrate that we can successfully remove Barrett’sesophagus and these studies are really a culmination.”This most recent study, he said, “specifically was intendedto validate the depth of penetration of the tissue asa result of applying the energy to the esophagus. It furthervalidated [that] the energy penetrated the tissue tobetween 700 microns and 100 microns and did not penetratethe sub-mucosal tissue. “In the largest study conducted (AIM-II Trial), 70% ofpatients were Barrett’s-free at one year follow-up. Clearly,key to the success for Barrx will be the more rapid diagnosisof Barrett’s esophagus and the awareness of cliniciansthat they can avoid prescribing a drug-only solution.The opportunity to take share from a pharmaceuticalregimen is huge. Barrett’s is estimated to affect about 3.3million adults in the U.S. with about 86,000 cases newlydiagnosed each year. “Boomers” especially may be at risksince the condition increases with age until a plateau isreached in the 60s, according to Barrx.The company last presented three studies demonstratingthe technology at Digestive Disease Week 2005 (MDD,May 19, 2005), and Barrett promised an increased numberof HALO 360 studies at Digestive Disease Week 2006, scheduledfor May 20-25 in Los Angeles. ■To subscribe, please call MEDICAL DEVICE DAILY Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.Copyright © 2006 Thomson BioWorld ® . Reproduction is strictly prohibited. Visit our web site at www.medicaldevicedaily.com.
TUESDAY, JANUARY 31, 2006 MEDICAL DEVICE DAILY PAGE 9 OF 10P EOPLE IN P LACES• Stephen T.D. Dixon, executive vice president and CFOof Clarient (San Juan Capistrano, California), will resignthose posts effective Feb. 3 to pursue a new professionalopportunity. He has served in those positions for Clarientsince December 2002. Clarient, a majority owned subsidiaryof Safeguard Scientifics, provides technologies, services andsupport for the characterization, assessment and treatmentof cancer via its Automated Cellular Imaging System.• Indira Pottathil, PhD, has been appointed the first directorof international marketing for Grant Life Sciences (LosAngeles). Since 1996, Pottathil has served as vice president ofR&D at AccuDx, where she managed compliance efforts aswell as development and production of in vitro diagnosticproducts. Grant Life Sciences develops products to detect anddiagnose cervical cancer, including a non-invasive, point-ofcaretest. It also markets rapid tests for malaria, Dengue fever,HIV-1 and HIV-2 that were acquired from AccuDx.• Rob Burrows, vice president and CFO of LightPathTechnologies (Orlando, Florida), has been named CFO ofFDN Communications, a provider of communications servicesin the Southeast, and has resigned his positions withLightPath effective Feb. 8. The company said Kenneth Brizel,president and CEO, would serve as acting CFO and actingprincipal financial and accounting officer while a search for areplacement for Burrows takes place. LightPath manufacturesoptical products including precision molded asphericoptics, Gradium glass products, collimator assemblies, lasercomponents, higher-level assemblies and packing solutions.• McKesson (San Francisco) has reported a series of managementchanges in its Pharmaceutical Solutions and Medical-Surgical Solutions segments, effective April 1. John Figueroa,president of retail national accounts for U.S. PharmaceuticalDistribution, becomes president, U.S. pharmaceutical distribution.Gary Muensterman, president, McKesson Medical-Surgical, becomes senior vice president, corporate strategyand business development. Brian Tyler, president, McKessonSpecialty Pharmaceutical, becomes president, McKessonMedical-Surgical. Patrick Blake, president, customer operationsfor U.S. Pharmaceutical Distribution, becomes president,McKesson Specialty Pharmaceutical, McKesson PharmacySystems and Automated Prescription Systems. McKesson is ahealthcare services and information technology company.• Christopher Wagner has been named senior vicepresidentof sales and marketing at MDS Nordion (Ottawa,Ontario). Wagner has nearly 30 years of global sales andmarketing experience, most recently with Tyco Healthcare/Mallinckrodt. MDS Nordion’s product lines include medicalisotopes for molecular imaging, development and manufacturingof radiotherapeutics, and sterilization productsand services for the diagnosis, prevention and treatment ofdisease.Medical Alley/MNBIO addstwo vice presidents to staffA Medical Device Daily Staff ReportMedical Alley/MNBIO (St. Louis Park, Minnesota), alife sciences trade association serving Minnesota andsurrounding areas, has added two new vice presidents toits staff. Dana Boyle will serve as vice president for businessdevelopment, with a focus on bioscience, and LarryKuusisto, PhD, is the new vice president of education andexecutive director of Alley Institute.Boyle has served for the past 20 years as a tradecommissioner at the Consulate General of Canada inMinneapolis, where she built relationships betweenthe business and scientific communities, bridgingCanada to the Upper Midwest and Rocky Mountainstates.She has focused on the biosciences and environmentalsectors to grow what Medical Alley/MNBIO characterizedas “a strong network of contacts including smallcompanies, large corporations, research institutions,industry associations, universities and government tradeand investment offices on both sides of the border —with an objective to help create a solid and well-roundedcorridor throughout Minnesota and the surroundingregion.”Kuusisto has served Medical Alley for 12 years onthe organization’s Government Committee and threeyears on its board of directors. In 2004, he designedand implemented a community decision-makingprocess determining consumer healthcare coveragestemming from Alley Institute’s “Town Hall” convenerinitiative.He recently completed a postdoctoral fellowship inhealth services research and policy in the School ofPublic Health at the University of Minnesota, and previouslyserved in a number of roles at Northwestern HealthSciences University. Kuusisto directs the MinnesotaPalliative Care Partnership and will continue in that rolethrough Alley Institute.Medical Alley/MNBIO President and CEO Don Gerhardtsaid the two additions “bring the expertise andexperience that will greatly enhance the programs webring to our members and the life sciences communitythat benefit from this organization’s services.”He added: “We believe the surrounding states andCanadian provinces possess common attributes, challengesand great potential — and with closer collaboration,including how we inform and educate, this regionwill be highly successful in addressing key health andenvironmental issues.”Medical Alley/MNBIO is comprised of more than 500life science member organizations employing about250,000.To subscribe, please call MEDICAL DEVICE DAILY Customer Service at (800) 688-2421; outside the U.S. and Canada, call (404) 262-5476.Copyright © 2006 Thomson BioWorld ® . Reproduction is strictly prohibited. Visit our web site at www.medicaldevicedaily.com.
Page 1: TUESDAY, JANUARY 31, 2006 VOL. 10,
Page 4 and 5: TUESDAY, JANUARY 31, 2006 MEDICAL D
Page 6 and 7: TUESDAY, JANUARY 31, 2006 MEDICAL D
Page 10: TUESDAY, JANUARY 31, 2006 MEDICAL D

INSIDE: - Medical Device Daily

Create successful ePaper yourself

Delete template?

Save as template?